-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

2742 Safety and Efficacy of Arsenic Trioxide in the Treatment of Newly Diagnosed Pediatric Acute Promyelocytic Leukemia: Results from the JPLSG AML-P13 Study

Program: Oral and Poster Abstracts
Session: 615. Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster II
Hematology Disease Topics & Pathways:
Acute Myeloid Malignancies, APL, Combination therapy, Diseases, Myeloid Malignancies
Sunday, December 11, 2022, 6:00 PM-8:00 PM

Hiroyuki Takahashi, MD, PhD1*, Shiro Tanaka, PhD2*, Yuki Yuza, MD, PhD3*, Yuka Iijima-Yamashita, PhD4*, Daisuke Hasegawa, MD, PhD5*, Hiroshi Moritake, MD, PhD6, Kiminori Terui, MD, PhD7*, Shotaro Iwamoto, MD8*, Akira Shimada, MD, PhD9, Jun Matsubayashi, PhD10*, Takao Deguchi, MD, PhD11, Yoshiko Hashii, MD, PhD12, Nobutaka Kiyokawa, MD, PhD13*, Hayato Miyachi, MD, PhD14*, Akiko Moriya Saito, MD, PhD15*, Takashi Taga, MD, PhD16*, Souichi Adachi, MD, PhD17 and Daisuke Tomizawa, MD, PhD18

1Department of Pediatrics, Toho University, Tokyo, Japan
2Department of Clinical Biostatistics, Graduate School of Medicine, Kyoto University, Kyoto, Japan
3Department of Hematology-Oncology, Tokyo Metropolitan Children's Medical Center, Tokyo, Japan
4Clinical Research Center, National Hospital Organization Nagoya Medical Center, Aichi, JPN
5Department of Pediatrics, St. Luke's International Hospital, Tokyo, Japan
6Division of Pediatrics, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan
7Department of Pediatrics, Hirosaki University Graduate School of Medicine, Hirosaki, Japan
8Department of Pediatrics, Mie University Graduate School of Medicine, Tsu, Japan
9Department of Pediatrics, Jichi Medical University Hospital, Tochigi, Japan
10Center for Clinical Research and Advanced Medicine, Shiga University of Medical Science, Otsu, Japan
11Division of Cancer Immunodiagnostics, Children’s Cancer Center, National Center for Child Health and Development, Tokyo, Japan
12Department of Pediatrics, Osaka International Cancer Institute, Osaka, Japan
13Department of Pediatric Hematology and Oncology Research, Research Institute, National Center for Child Health and Development, Tokyo, Japan
14Department of Laboratory Medicine, Tokai University School of Medicine, Isehara, Japan
15Clinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Japan
16Department of Pediatrics, Shiga University of Medical Science, Otsu, Japan
17Department of Human Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto, Japan
18Division of Leukemia and Lymphoma, Children's Cancer Center, National Center for Child Health and Development, Tokyo, Japan


Arsenic trioxide (ATO) has shown to be effective in patients with acute promyelocytic leukemia (APL), which has led to a dose reduction of cytotoxic agents in the treatment of APL. To investigate safety and efficacy of ATO in Japanese children with APL, we conducted a nationwide prospective study, JPLSG AML-P13 (jRCTs051180191).

Patients & Methods:

Between December 2014 and November 2018, children (0-18 years old) with newly diagnosed APL were enrolled in the AML-P13 study. All patients received two courses of induction therapy consisting of ATRA, cytarabine, and daunorubicin. Patients who achieved hematological complete remission (HCR) were allocated to the standard risk (SR) group and received three intensification cycles consisting of ATRA and ATO, followed by intermittent ATRA maintenance therapy. Patients who did not obtain HCR after induction courses were allocated to the high risk (HR) group and received intensified schedule of ATO, followed by gemtuzumab ozogamicin monotherapy and maintenance therapy consisting of 6-mercaptopurine and methotrexate.

Results & Discussions:

Among the 32 patients registered, 5 patients were excluded due to a lack of PML::RARA fusion or other reasons, and the remaining 27 patients received the protocol therapy (full analysis set). During induction courses, grade 3­ disseminated intravascular coagulation was observed in 9 patients (33.3%). APL differentiation syndrome and induction death were not reported. Two patients were taken off protocol therapy due to a progressive disease (regarded as an event) and a safety issue, respectively. Among the 25 patients who completed induction therapy, 23 patients obtained HCR. During intensification cycles of ATO, grade 3 or higher non-hematological adverse events (AEs) were observed in 3 patients: prolonged QTc interval in 2 and dysesthesia in one. Regarding hematological AEs, 10 to 30% patients exhibited grade 4 neutropenia during each intensification cycles, but no patients experienced severe infectious complications. Two patients who did not obtain HCR received HR regimen without any apparent AEs. All 25 patients including 2 HR patients achieved molecular remission at the end of intensification and molecular remission rate was 100.0% [95% C.I. 86.3-100.0%]. No patients suffered from relapse, and 3-year EFS rate and 3-year OS rate in full analysis set were 96.3% [76.5-99.5%] (Figure) and 100.0% [87.2-100.0%], respectively. We previously reported an inferior outcome of younger children (less than 5 years old) treated with conventional ATRA and chemotherapy in the JPLSG AML-P05 study (Takahashi H. Br J Haematol 2016). However, 4 children under 5 years of age at diagnosis in the AML-P13 study remains in molecular remission, indicating efficacy of ATO in this age group of children.


The AML-P13 study demonstrated an excellent outcome in children with APL and showed that ATO could be administered safely in children with APL.

Disclosures: Tomizawa: Novartis: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau.

*signifies non-member of ASH